LGALS3 and hepatocellular carcinoma: Specifically, galectin-3 is reportedly activated in cirrhotic liver and HCC (Hsu et al., 1999), and high circulating levels are associated with poor prognosis in patients with primary HCC, corroborating our results (Jiang et al., 2014).